What is Ultragenyx Pharmaceutical's preferred stock?

Ultragenyx Pharmaceutical (RARE) reported preferred stock of $0 in Q1 2026.

What does preferred stock mean?

Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.

Ultragenyx Pharmaceutical RARE Preferred Stock

Preferred Stock at other companies

ModernaMRNA

$0—

Denali Therapeutics Inc.DNLI

$0—

BridgeBio PharmaBBIO

$0—

Catalyst PharmaceuticalCPRX

$0—

Dyne Therapeutics, Inc.DYN

$0—

LQD

Liquidia CorporationLQDA

$0—

Other financials

Income statement

See full

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

See full

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

See full

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

See full

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

See full

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

See full

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's preferred stock?: Ultragenyx Pharmaceutical (RARE) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?: Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.